Progress in the treatment of hypertension over the past 50 years is reviewed. While achievements have been considerable, they have sometimes been exaggerated by uncritical analyses and meta-analyses of trials. Data of the large but seriously flawed American HDFP study especially have distorted appreciation of therapeutic benefits. [References: 141]